Is Hyperliquid a good investment? The evidence describes a large, fee-generating trading business whose token captures part of those fees, set against concentrated validator control, a long unlock schedule and unresolved U.S. regulation. HYPE trades at $87.88, down 1.75% over 24 hours and up 15.08% over seven days. Its $21.04B market cap ranks #11, 24h volume is $1.88B, and the price sits 10.29% below the all-time high of $97.96.
Fundamental Strengths
Hyperliquid's onchain perpetuals exchange is the core business. Castle Labs reports it holds over 56% of onchain perp open interest, ahead of Aster at 9.7% and Lighter at 5.7% (Castle Labs). Under the protocol's design, 99% of perp fees go to the Assistance Fund, which buys HYPE on the open market and burns it. Cumulative buybacks exceeded $1.26B as of 8 October 2026, according to Castle Labs.
Market Position and Competitive Pressure
Market share is falling from its peak. Arongroups states that Hyperliquid's share was about 70% at its 2025 peak (Arongroups). Lighter's monthly volume fell from about $232B in December 2025 to about $39B by May 2026. Fully diluted valuation is $83.63B, more than three times the market cap, so much of the supply is not yet priced into the circulating float.
Revenue and Buyback Sustainability
Hyperliquid's 2025 net protocol revenue was about $857M, and monthly fees reached $75.4M in September 2026 (Datawallet). Buyback dollars depend on trading volume. Dollar buybacks have fallen about 70% from their 2025 peak, according to hl.eco, and QuantAbundance describes the buyback as "a claim on volume, not a floor" (QuantAbundance).
Governance and Validator Concentration
Hyperliquid Labs, led by Jeff Yan, states that it is self-funded and has taken no external capital. Five validators labeled as Hyper Foundation hold about 48.7% to 48.9% of active stake. That figure is down from over 81% in early 2025 (Investing.com).
The March 2025 JELLY incident showed how validators can override market outcomes. Validators settled JELLY at $0.0095 while decentralized exchange oracles showed about $0.50, and the HLP vault faced losses of roughly $12M to $13.5M (CoinDesk). Critics argue that the intervention contradicted the protocol's decentralized framing.
Regulatory and Technical Risk
In May 2026, CME and ICE reportedly urged U.S. regulators to scrutinize Hyperliquid over manipulation risks (CoinDesk). On 29 September 2026, the House Oversight Committee wrote to Yan about prediction-market trading. A former SEC senior counsel estimated a 10-to-12-month process for U.S. access. USDC is the primary margin and settlement currency, so a stablecoin de-peg is a cited risk. A network upgrade is scheduled for 31 October 2026, with about 10 minutes of expected downtime.
Institutional Interest and Holders
Three U.S. spot ETFs held $502M in net assets on 25 September 2026. Cumulative net inflows were $342M, down from a $356.6M peak on 4 September (Yahoo Finance). JPMorgan reports that inflows largely stalled in July and August (CoinDesk). Hyperliquid Strategies held about 29.4M HYPE as of 23 August 2026, with substantially all of it held by one custodian (Hyperliquid Strategies 10-K).
Token Supply and Unlocks
The maximum supply is 1 billion HYPE. Circulating supply is 239,406,814 HYPE against a total supply of 951,538,273 HYPE, so roughly 75% of supply remains outside circulation. Core contributors hold 23.8% of supply, or 238M HYPE, vesting monthly through 2027 and 2028 (Hyperliquid Strategies 10-K).
Bull Case
- Fee-funded buybacks link token demand to real trading activity.
- Blocmates' base case assumes Hyperliquid's perp DEX share grows to 50% by 2032 (Blocmates).
- Builder-deployed markets (HIP-3) grew from about 2% of Hyperliquid's perp volume at the start of 2026 to nearly 50% by mid-July.
Bear Case
- Share of perp DEX volume has fallen from its 2025 peak.
- Five validators control nearly half of active stake, and validators have overridden oracle-based outcomes.
- Unlocks continue monthly through 2028.
- ETF inflows have stalled, and the U.S. regulatory path remains open.
Risk/Reward Assessment
The upside depends on share gains in onchain perpetuals, U.S. market access and sustained volume that keeps buybacks funded. The downside rests on validator concentration, regulatory timing, dependence on USDC and a supply schedule that runs into 2028. The outcome is most sensitive to whether regulatory access arrives and whether validator concentration keeps declining.